Aummune

AummuneAummune
Aummune

Aummune

Develops a platform for individual drug customization using aptamers for cancer treatment.

DR 17Speed 662017Active6San Diego, United States
Rate

About

Aummune is a clinical-stage company developing a novel, individualized immunotherapy for solid tumors. Their proprietary platform utilizes an efficacy-driven selection process to create patient-specific tri-functional oligonucleotide drugs that induce cancer cell death and activate immune responses. This approach aims to provide a new class of therapy for a broad spectrum of cancer indications.
Frequently asked

What does Aummune do?

Aummune is a clinical-stage company developing a novel, individualized immunotherapy for solid tumors. Their proprietary platform utilizes an efficacy-driven selection process to create patient-specific tri-functional oligonucleotide drugs that induce cancer cell death and activate immune responses. This approach aims to provide a new class of therapy for a broad spectrum of cancer indications.

What is Aummune's revenue?

StartupHub estimates Aummune's annual revenue at $1.0M (range $572K to $1.6M, 64% confidence), based on comparable companies in the sector.

What is Aummune's valuation?

StartupHub estimates Aummune's effective valuation at $39.8M (range $25.0M to $60.0M, 10% confidence), based on comparable companies in the sector.

How much funding has Aummune raised?

Aummune has raised a total of $10M in funding. The most recent round on record is Series A.

Where is Aummune headquartered?

Aummune is headquartered in San Diego, United States.

When was Aummune founded?

Aummune was founded in 2017.

What industry does Aummune operate in?

Aummune operates in Life Sciences, Cancer, Therapeutics, Biotech, Personalized Treatment, Drug Discovery.

How many employees does Aummune have?

Aummune has approximately 6 people on record.

HEADCOUNT
6
DOMAIN RATING
17
Comments

No comments yet. Be the first to share your take.